Eurizon Capital SGR S.p.A. Takes Position in Insulet Corporation $PODD

Eurizon Capital SGR S.p.A. acquired a new stake in shares of Insulet Corporation (NASDAQ:PODD) in the fourth quarter, HoldingsChannel.com reports. The fund acquired 27,215 shares of the medical instruments supplier’s stock, valued at approximately $7,741,000.

Other institutional investors have also recently made changes to their positions in the company. Larson Financial Group LLC boosted its stake in shares of Insulet by 114.6% during the fourth quarter. Larson Financial Group LLC now owns 88 shares of the medical instruments supplier’s stock valued at $25,000 after purchasing an additional 47 shares during the period. Elyxium Wealth LLC purchased a new stake in shares of Insulet during the fourth quarter valued at approximately $28,000. Fideuram Asset Management Ireland dac purchased a new stake in shares of Insulet during the fourth quarter valued at approximately $41,000. Measured Wealth Private Client Group LLC purchased a new stake in shares of Insulet during the third quarter valued at approximately $49,000. Finally, Osterweis Capital Management Inc. purchased a new stake in shares of Insulet during the second quarter valued at approximately $51,000.

Insulet Stock Performance

PODD opened at $144.94 on Monday. The company has a quick ratio of 1.81, a current ratio of 2.49 and a debt-to-equity ratio of 0.71. Insulet Corporation has a 52 week low of $140.63 and a 52 week high of $354.88. The stock has a market cap of $10.04 billion, a PE ratio of 33.71, a PEG ratio of 1.14 and a beta of 1.13. The business has a 50 day moving average of $183.55 and a 200-day moving average of $244.77.

Insulet (NASDAQ:PODD) last posted its quarterly earnings data on Wednesday, May 6th. The medical instruments supplier reported $1.42 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.19 by $0.23. The business had revenue of $761.70 million during the quarter, compared to the consensus estimate of $729.89 million. Insulet had a return on equity of 26.87% and a net margin of 10.44%.The firm’s quarterly revenue was up 33.9% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.02 earnings per share. Insulet has set its FY 2026 guidance at 6.210- EPS. Equities research analysts predict that Insulet Corporation will post 6.44 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on PODD. Royal Bank Of Canada reiterated an “outperform” rating and issued a $280.00 price objective on shares of Insulet in a research report on Wednesday, May 27th. Raymond James Financial cut their price objective on Insulet from $355.00 to $263.00 in a research report on Thursday, May 7th. Stifel Nicolaus cut their price objective on Insulet from $350.00 to $250.00 in a research report on Thursday, May 7th. William Blair began coverage on Insulet in a research report on Wednesday, May 20th. They issued an “outperform” rating on the stock. Finally, Robert W. Baird cut their price objective on Insulet from $360.00 to $248.00 in a research report on Thursday, May 7th. Twenty-one analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $252.04.

About Insulet

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.